Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma-Reference-Cited by-同舟云学术

Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma

Published:2017-07-20 Issue:3 Volume:130 Page:267-270
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Zinzani Pier Luigi¹,Ribrag Vincent²,Moskowitz Craig H.³,Michot Jean-Marie²,Kuruvilla John⁴,Balakumaran Arun⁵,Zhang Yayan⁵,Chlosta Sabine⁵,Shipp Margaret A.⁶,Armand Philippe⁶

Affiliation:

1. Institute of Hematology “L. e A. Seràgnoli,” University of Bologna, Bologna, Italy;

2. Gustave Roussy, Université Paris-Saclay, Département d'hématologie, INSERM U1170, Villejuif, France;

3. Memorial Sloan Kettering Cancer Center, New York, NY;

4. Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada;

5. Merck & Co., Inc., Kenilworth, NJ; and

6. Dana-Farber Cancer Institute, Boston, MA

Abstract

Key Points Treatment options for relapsed/refractory PMBCL are limited, and prognosis is generally poor. Pembrolizumab had a manageable safety profile and promising antitumor activity in heavily pretreated rrPMBCL patients.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/130/3/267/1404960/blood758383.pdf

Reference18 articles.

1. Primary mediastinal large B-cell lymphoma;Bhatt;Cancer Treat Rev,2015

2. Primary mediastinal lymphoma: diagnosis and treatment options;Martelli;Expert Rev Hematol,2015

3. National Cancer Institute. Surveillance, Epidemiology, and End Results Program website. Available from URL: http://seer.cancer.gov/. Accessed 20 February 2017.

4. Current trends in the treatment of primary mediastinal large B-cell lymphoma - an overview;Petković;Contemp Oncol (Pozn),2015

5. Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients;Lazzarino;J Clin Oncol,1997

Cited by 249 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PD-1 inhibitor in the treatment of relapsed primary mediastinal large B-cell lymphoma follow up by 18F-FDG PET/CT: A case report and literature review;Radiology Case Reports;2024-10

2. Chidamide plus R‐GDP for relapsed/refractory diffuse large B‐cell lymphoma in patients ineligible for autologous transplantation: A prospective, single‐arm, phase II study;Cancer Medicine;2024-08

3. Novel Targets and Advanced Therapies in Diffuse Large B Cell Lymphomas;Cancers;2024-06-17

4. Programmed Death Ligand 1 (PD-L1) Expression in Lymphomas: State of the Art;International Journal of Molecular Sciences;2024-06-11

5. Regulatory mechanisms of PD-1/PD-L1 in cancers;Molecular Cancer;2024-05-18